loading page

Evaluation of the Diagnostic Value of Extra-criteria Antibodies for Antiphospholipid Syndrome Patients in a Chinese Cohort
  • +10
  • Chaojun Hu,
  • Siting Li,
  • Zhijuan Xie,
  • Hanxiao You,
  • Hui Jiang,
  • Yu Shi,
  • Wanting Qi,
  • Jiuliang Zhao,
  • Qian Wang,
  • Xinping Tian,
  • Mengtao Li,
  • Yan Zhao,
  • Xiaofeng Zeng
Chaojun Hu
Peking Union Medical College Hospital
Author Profile
Siting Li
Peking Union Medical College Hospital
Author Profile
Zhijuan Xie
Peking Union Medical College Hospital
Author Profile
Hanxiao You
Peking Union Medical College Hospital
Author Profile
Hui Jiang
Peking Union Medical College Hospital
Author Profile
Yu Shi
Peking Union Medical College Hospital
Author Profile
Wanting Qi
Peking Union Medical College Hospital
Author Profile
Jiuliang Zhao
Peking Union Medical College Hospital
Author Profile
Qian Wang
Peking Union Medical College Hospital
Author Profile
Xinping Tian
Peking Union Medical College Hospital
Author Profile
Mengtao Li
Peking Union Medical College Hospital
Author Profile
Yan Zhao
Peking Union Medical College Hospital
Author Profile
Xiaofeng Zeng
Peking Union Medical College Hospital
Author Profile

Abstract

Objective: Although specific anti-phospholipids antibodies (aPLs) have been used in the diagnosis of the antiphospholipid syndrome (APS) for years, new biomarkers are required to increase its diagnostic as well as risk-predictive power. This study aimed to explore the value of several extra-criteria aPLs in a Chinese cohort. Methods: A total of 312 patients including 100 patients diagnosed with primary APS, 51 with APS secondary to SLE, 71 with SLE, and 90 health controls were recruited. Serum anticardiolipin (aCL) IgG/IgM/IgA, anti-β2-glycoprotein I (aβ2GPI) IgG/IgM/IgA, anti-phosphatidylserine/prothrombin antibodies (aPS/PT) IgG/IgM, anti-annexin A5 antibodies (aAnxV) IgG/IgM were tested using ELISA kits. Results: Totally 30.46% and 6.62% of patients with APS were positive for aCL or aβ2GPI IgA respectively, while 39.07% and 24.50% were positive for aAnxV or aPS/PT for at least one antibodies (IgG or IgM). The addition test of aCL IgA and aAnxV IgM assist in identifying seronegative APS patients, and IgG aANxV was linked with stroke. Conclusion: Detection of aCL IgA, aβ2GPI IgA, aAnxV IgG/M, and aPS/PT IgG/M as biomarker provide additive value in APS diagnosis, and would help in risk prediction for APS patients in medical practice.